BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30204961)

  • 1. PHENOTYPIC CONSEQUENCES AND THE MALIGNANCY RISK IN FAMILIAL NOONAN SYNDROME DUE TO A RARE P.S427G RAF1 MUTATION.
    Pelc M; Ciara E; Jezela-Stanek A; Krajewska-Walasek M
    Genet Couns; 2016; 27(3):325-333. PubMed ID: 30204961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor.
    Harms FL; Alawi M; Amor DJ; Tan TY; Cuturilo G; Lissewski C; Brinkmann J; Schanze D; Kutsche K; Zenker M
    Am J Med Genet A; 2018 Feb; 176(2):470-476. PubMed ID: 29271604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal pulmonary arterial hypertension and Noonan syndrome: two fatal cases with a specific RAF1 mutation.
    Hopper RK; Feinstein JA; Manning MA; Benitz W; Hudgins L
    Am J Med Genet A; 2015 Apr; 167A(4):882-5. PubMed ID: 25706034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations.
    Denayer E; Devriendt K; de Ravel T; Van Buggenhout G; Smeets E; Francois I; Sznajer Y; Craen M; Leventopoulos G; Mutesa L; Vandecasseye W; Massa G; Kayserili H; Sciot R; Fryns JP; Legius E
    Genes Chromosomes Cancer; 2010 Mar; 49(3):242-52. PubMed ID: 19953625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation.
    Kobayashi T; Aoki Y; Niihori T; Cavé H; Verloes A; Okamoto N; Kawame H; Fujiwara I; Takada F; Ohata T; Sakazume S; Ando T; Nakagawa N; Lapunzina P; Meneses AG; Gillessen-Kaesbach G; Wieczorek D; Kurosawa K; Mizuno S; Ohashi H; David A; Philip N; Guliyeva A; Narumi Y; Kure S; Tsuchiya S; Matsubara Y
    Hum Mutat; 2010 Mar; 31(3):284-94. PubMed ID: 20052757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome.
    Ko JM; Kim JM; Kim GH; Yoo HW
    J Hum Genet; 2008; 53(11-12):999-1006. PubMed ID: 19020799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline gain-of-function mutations in RAF1 cause Noonan syndrome.
    Razzaque MA; Nishizawa T; Komoike Y; Yagi H; Furutani M; Amo R; Kamisago M; Momma K; Katayama H; Nakagawa M; Fujiwara Y; Matsushima M; Mizuno K; Tokuyama M; Hirota H; Muneuchi J; Higashinakagawa T; Matsuoka R
    Nat Genet; 2007 Aug; 39(8):1013-7. PubMed ID: 17603482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noonan syndrome associated with both a new Jnk-activating familial SOS1 and a de novo RAF1 mutations.
    Longoni M; Moncini S; Cisternino M; Morella IM; Ferraiuolo S; Russo S; Mannarino S; Brazzelli V; Coi P; Zippel R; Venturin M; Riva P
    Am J Med Genet A; 2010 Sep; 152A(9):2176-84. PubMed ID: 20683980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A severe clinical phenotype of Noonan syndrome with neonatal hypertrophic cardiomyopathy in the second case worldwide with RAF1 S259Y neomutation.
    Jaouadi H; Chehida AB; Kraoua L; Etchevers HC; Argiro L; Kasdallah N; Blibech S; Delague V; Lévy N; Tebib N; Mrad R; Abdelhak S; Benkhalifa R; Zaffran S
    Genet Res (Camb); 2019 Apr; 101():e6. PubMed ID: 31030682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.
    Wu X; Simpson J; Hong JH; Kim KH; Thavarajah NK; Backx PH; Neel BG; Araki T
    J Clin Invest; 2011 Mar; 121(3):1009-25. PubMed ID: 21339642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants.
    Wu X; Yin J; Simpson J; Kim KH; Gu S; Hong JH; Bayliss P; Backx PH; Neel BG; Araki T
    Mol Cell Biol; 2012 Oct; 32(19):3872-90. PubMed ID: 22826437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of gene dosage imbalances in patients with Noonan syndrome using multiplex ligation-dependent probe amplification analysis.
    Nyström AM; Ekvall S; Thuresson AC; Denayer E; Legius E; Kamali-Moghaddam M; Westermark B; Annerén G; Bondeson ML
    Eur J Med Genet; 2010; 53(3):117-21. PubMed ID: 20302979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
    Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
    Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
    Zebisch A; Staber PB; Delavar A; Bodner C; Hiden K; Fischereder K; Janakiraman M; Linkesch W; Auner HW; Emberger W; Windpassinger C; Schimek MG; Hoefler G; Troppmair J; Sill H
    Cancer Res; 2006 Apr; 66(7):3401-8. PubMed ID: 16585161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A boy with Burkitt lymphoma associated with Noonan syndrome due to a mutation in RAF1.
    Cianci P; Tono V; Sala A; Locatelli L; Carta C; Rizzari C; Biondi A; Selicorni A
    Am J Med Genet A; 2013 Jun; 161A(6):1401-4. PubMed ID: 23613113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical profile of comorbidity of rare diseases in a Tunisian patient: a case report associating incontinentia pigmenti and Noonan syndrome.
    Ghedira N; Lagarde A; Ben Ameur K; Elouej S; Sakka R; Kerkeni E; Chioukh FZ; Olschwang S; Desvignes JP; Abdelhak S; Delague V; Lévy N; Monastiri K; De Sandre-Giovannoli A
    BMC Pediatr; 2018 Aug; 18(1):286. PubMed ID: 30157809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation in NRAS in familial Noonan syndrome--case report and review of the literature.
    Ekvall S; Wilbe M; Dahlgren J; Legius E; van Haeringen A; Westphal O; Annerén G; Bondeson ML
    BMC Med Genet; 2015 Oct; 16():95. PubMed ID: 26467218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype.
    Martinelli S; De Luca A; Stellacci E; Rossi C; Checquolo S; Lepri F; Caputo V; Silvano M; Buscherini F; Consoli F; Ferrara G; Digilio MC; Cavaliere ML; van Hagen JM; Zampino G; van der Burgt I; Ferrero GB; Mazzanti L; Screpanti I; Yntema HG; Nillesen WM; Savarirayan R; Zenker M; Dallapiccola B; Gelb BD; Tartaglia M
    Am J Hum Genet; 2010 Aug; 87(2):250-7. PubMed ID: 20619386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
    Brasil AS; Pereira AC; Wanderley LT; Kim CA; Malaquias AC; Jorge AA; Krieger JE; Bertola DR
    Genet Test Mol Biomarkers; 2010 Jun; 14(3):425-32. PubMed ID: 20578946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.
    Swanson KD; Winter JM; Reis M; Bentires-Alj M; Greulich H; Grewal R; Hruban RH; Yeo CJ; Yassin Y; Iartchouk O; Montgomery K; Whitman SP; Caligiuri MA; Loh ML; Gilliland DG; Look AT; Kucherlapati R; Kern SE; Meyerson M; Neel BG
    Genes Chromosomes Cancer; 2008 Mar; 47(3):253-9. PubMed ID: 18064648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.